• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form S-3/A filed by Cel-Sci Corporation

    10/30/24 5:21:00 PM ET
    $CVM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $CVM alert in real time by email
    S-3/A 1 cvm_s3.htm FORM S-3 cvm_s3.htm

     

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM S-3

    AMENDMENT NO. 1

     

    Registration Statement Under

    THE SECURITIES ACT OF 1933

     

    CEL-SCI CORPORATION

    (Exact name of registrant as specified in charter)

     

    Colorado

    (State or other jurisdiction of incorporation)

     

    84-0916344

     

    8229 Boone Blvd. #802

    Vienna, Virginia 22182

    (703) 506-9460

    (IRS Employer I.D. Number)

     

    (Address, including zip code, and telephone number including area of principal executive offices)

     

    Geert Kersten

    8229 Boone Blvd. #802

    Vienna, Virginia 22182

    (703) 506-9460

    (Name and address, including zip code, and telephone number, including area code, of agent for service)

     

    Copies of all communications, including all communications sent

    to the agent for service, should be sent to:

     

    William T. Hart, Esq.

    Hart & Hart

    1624 Washington Street

    Denver, Colorado 80203

    (303) 839-0061

     

    As soon as practicable after the effective date of this Registration Statement

    APPROXIMATE DATE OF COMMENCEMENT OF PROPOSED SALE TO THE PUBLIC:

     

    If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933 check the following box: ☒

     

    If the only securities being registered on this form are being offered pursuant to dividend or interest reinvestment plans, please check the following box.   ☐

     

    If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

     

    If this Form is a post-effective amendment filed pursuant to Rule 462© under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

     

    If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer

    ☐

    Accelerated filer

    ☐

    Non-accelerated filer

    ☒

    Smaller reporting company

    ☒

    Emerging growth company

    ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

    The Registrant hereby amends the Registration Statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment that specifically states that the Registration Statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act, or until the Registration Statement shall become effective on such date as the Commission, acting pursuant to Section 8(a), may determine.

     

     

     

     

     

    EXPLANATORY NOTE

     

    This Amendment No. 1 is being filed to add the registrant’s Securities Purchase Agreement with Ergomed Group Limited as an exhibit to this Registration Statement.

      

     

     

      

    PART II

    Information Not Required in Prospectus

     

    Item 14. Other Expenses of Issuance and Distribution.

     

    The following table shows the costs and expenses payable by the Company in connection with this registration statement.

     

    SEC Filing Fee

     

    $ 138

    * 

    Legal Fees and Expenses

     

     

    4,000

     

    Accounting Fees and Expenses

     

     

    24,000

     

    Miscellaneous Expenses

     

     

    862

     

    TOTAL

     

    $ 29,000

     

     

    * Previously Paid 

    All expenses other than the SEC filing fee are estimated.

     

    Item 15. Indemnification of Officers and Directors

     

    The Colorado Business Corporation Act provides that the Company may indemnify any and all of its officers, directors, employees or agents or former officers, directors, employees or agents, against expenses actually and necessarily incurred by them, in connection with the defense of any legal proceeding or threatened legal proceeding, except as to matters in which such persons shall be determined to not have acted in good faith and in the Company’s best interest.

     

    Item 16. Exhibits

     

     

    4

    Securities Purchase Agreement between CEL-SCI Corporation and Ergomed Group Limited, dated October 18, 2024 .

    _____________

     

     

     

     

    5

    Legal Opinion

    Previously filed

     

     

     

     

    23.1

    Consent of Hart & Hart, LLC

    Previously filed

     

     

     

     

    23.2

    Consent of BDO USA, P.C.

    Previously filed

     

     

     

     

    107

    Calculation of Filing Fee Table

    Previously filed

     

     
    2

     

     

    Item 17. Undertakings

     

    The undersigned registrant hereby undertakes:

     

    (1)

    To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:

     

     

    (a)

    To include any prospectus required by Section 10(a)(3) of the Securities Act of 1933,

     

     

     

     

    (b)

    To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20 percent change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective registration statement,

     

     

     

     

    (c)

    To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement.

     

    Provided, however, that paragraphs (1)(a), (1)(b) and (1)(c) above do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in periodic reports filed with or furnished to the Commission by the registrant pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 that are incorporated by reference in the registration statement, or is contained in a form of prospectus filed pursuant to Rule 424(b) that is part of the registration statement.

     

    (2)

    That, for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

     

    (3)

    To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

     

     

    (4)

    That, for the purpose of determining liability under the Securities Act of 1933 to any purchaser:

     

     

    (a)

    Each prospectus filed by the registrant pursuant to Rule 424(b)(3) shall be deemed to be part of the registration statement as of the date the filed prospectus was deemed part of and included in the registration statement; and

     

     

     

     

    (b)

    Each prospectus required to be filed pursuant to Rule 424(b)(2), (b)(5), or (b)(7) as part of a registration statement in reliance on Rule 430B relating to an offering made pursuant to Rule 415(a)(1)(i), (vii), or (x) for the purpose of providing the information required by section 10(a) of the Securities Act of 1933 shall be deemed to be part of and included in the registration statement as of the earlier of the date such form of prospectus is first used after effectiveness or the date of the first contract of sale of securities in the offering described in the prospectus. As provided in Rule 430B, for liability purposes of the issuer and any person that is at that date an underwriter, such date shall be deemed to be a new effective date of the registration statement relating to the securities in the registration statement to which that prospectus relates, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. Provided, however, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such effective date, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such effective date

     

     
    3

     

     

    (5)

    That, for purposes of determining any liability under the Securities Act of 1933, each filing of the registrant’s annual report pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Securities Exchange Act of 1934) that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

     

    (6)

    Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the registrant pursuant to the forgoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Act and will be governed by the final adjudication of such issue.

     

     
    4

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of l933, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the Vienna, Virginia on the 30th day of October, 2024.

     

     

    CEL-SCI CORPORATION

     

     

     

     

     

     

    By:  

    /s/ Geert Kersten

     

     

     

    Geert Kersten

     

     

     

    Chief Executive, Financial and Accounting Officer

     

     

    In accordance with the requirements of the Securities Act of l933, this registration statement has been signed by the following persons in the capacities and on the dates indicated:

     

    Signature

     

    Title

     

    Date

     

     

     

     

     

    /s/ Geert Kersten

     

    Chief Executive, Financial and Accounting Officer and a Director

     

    October 30, 2024

    Geert Kersten

     

     

     

     

     

     

     

     

     

    /s/ Bruno Baillavoine

     

    Director

     

    October 30, 2024

    Bruno Baillavoine 

     

     

     

     

     

     

     

     

     

    /s/ Robert Watson

     

    Director, Chairman of the Board

     

    October 30, 2024

    Robert Watson

     

     

     

     

     

     

     

     

     

    /s/ Mario Gobbo

     

    Director

     

    October 30, 2024

    Mario Gobbo

     

     

     

     

     

     
    5

     

     

    EXHIBITS

     

    CEL-SCI CORPORATION

     

    REGISTRATION STATEMENT ON FORM S-3

     

     
    6

     

    Get the next $CVM alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CVM

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $CVM
    SEC Filings

    View All

    SEC Form EFFECT filed by Cel-Sci Corporation

    EFFECT - CEL SCI CORP (0000725363) (Filer)

    12/4/25 12:15:16 AM ET
    $CVM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Cel-Sci Corporation filed SEC Form 8-K: Material Modification to Rights of Security Holders, Financial Statements and Exhibits

    8-K - CEL SCI CORP (0000725363) (Filer)

    11/24/25 5:00:37 PM ET
    $CVM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form S-3 filed by Cel-Sci Corporation

    S-3 - CEL SCI CORP (0000725363) (Filer)

    11/7/25 4:31:11 PM ET
    $CVM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CVM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Kersten Geert R bought $200,001 worth of shares (38,023 units at $5.26), increasing direct ownership by 46% to 120,815 units (SEC Form 4)

    4 - CEL SCI CORP (0000725363) (Issuer)

    1/26/26 8:23:27 AM ET
    $CVM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Scientific Officer Talor Eyal was granted 456 shares, increasing direct ownership by 8% to 6,264 units (SEC Form 4)

    4 - CEL SCI CORP (0000725363) (Issuer)

    1/5/26 9:30:02 AM ET
    $CVM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Financial Officer Prichep Patricia B was granted 815 shares, increasing direct ownership by 7% to 12,028 units (SEC Form 4)

    4 - CEL SCI CORP (0000725363) (Issuer)

    1/5/26 9:26:57 AM ET
    $CVM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CVM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Kersten Geert R bought $200,001 worth of shares (38,023 units at $5.26), increasing direct ownership by 46% to 120,815 units (SEC Form 4)

    4 - CEL SCI CORP (0000725363) (Issuer)

    1/26/26 8:23:27 AM ET
    $CVM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Executive Officer Kersten Geert R bought $49,998 worth of shares (8,389 units at $5.96), increasing direct ownership by 11% to 81,794 units (SEC Form 4)

    4 - CEL SCI CORP (0000725363) (Issuer)

    12/5/25 8:48:04 AM ET
    $CVM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Watson Robert Eugene bought $19,995 worth of shares (2,919 units at $6.85), increasing direct ownership by 359% to 3,733 units (SEC Form 4)

    4 - CEL SCI CORP (0000725363) (Issuer)

    7/29/25 7:56:00 AM ET
    $CVM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CVM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    CEL-SCI Reports Fiscal 2025 Results

    Filed for Breakthrough Designation for Multikine in Saudi Arabia A 212-patient Confirmatory Registration Study for Multikine in PD-L1 low newly diagnosed head and neck cancer patients is currently in final stage of preparations - enrollment expected to begin Spring 2026 Plans to seek early approval in U.S. based on pre-surgical response rate upon full enrollment CEL-SCI Corporation (NYSE:CVM) reported financial results for the fiscal year ended September 30, 2025, as well as key clinical and corporate developments. "During fiscal 2025, our regulatory advancements accelerated driven by new opportunities for Multikine in Saudi Arabia and the green light we have received for our Co

    12/29/25 9:00:00 AM ET
    $CVM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    CEL-SCI Announces Closing of $10 Million Public Offering

    CEL-SCI Corporation ("CEL-SCI" or the "Company") (NYSE:CVM), a clinical stage cancer immunotherapy company, today announced the closing of its offering of 1,111,200 shares of its common stock. Each share of common stock was sold at a public offering price of $9.00 per share. Total gross proceeds from the offering, before deducting the placement agent's fees and other offering expenses, were approximately $10 million. The Company intends to use the net proceeds from the offering to fund the continued development of Multikine, general corporate purposes, and working capital. ThinkEquity acted as the sole placement agent for the offering. The securities were offered and sold pursuant to

    8/29/25 12:52:00 PM ET
    $CVM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    CEL-SCI Announces Pricing of $10 Million Public Offering

    CEL-SCI Corporation ("CEL-SCI" or the "Company") (NYSE:CVM), a clinical stage cancer immunotherapy company, today announced the pricing of a best-efforts public offering of 1,111,200 shares of its common stock. Each share of common stock is being sold at a public offering price of $9.00 per share. Total gross proceeds from the offering, before deducting the placement agent's fees and other offering expenses, are expected to be approximately $10 million. The offering is expected to close on August 29, 2025, subject to satisfaction of customary closing conditions. The Company intends to use the net proceeds from the offering to fund the continued development of Multikine, general corporate

    8/27/25 10:35:00 PM ET
    $CVM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CVM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Cel-Sci Corporation (Amendment)

    SC 13G/A - CEL SCI CORP (0000725363) (Subject)

    2/8/23 10:48:28 AM ET
    $CVM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by Cel-Sci Corporation (Amendment)

    SC 13G/A - CEL SCI CORP (0000725363) (Subject)

    4/11/22 1:55:14 PM ET
    $CVM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by Cel-Sci Corporation (Amendment)

    SC 13G/A - CEL SCI CORP (0000725363) (Subject)

    2/11/22 7:53:04 AM ET
    $CVM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CVM
    Leadership Updates

    Live Leadership Updates

    View All

    CEL-SCI Corporation Reports Third Quarter Fiscal 2024 Financial Results

    CEL-SCI Corporation (NYSE:CVM) today reported financial results for the quarter ended June 30, 2024, as well as key recent clinical and corporate developments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240815767286/en/The table includes detailed results from the bias analysis. (Graphic: Business Wire) Clinical and Corporate Developments include: In July 2024, following the end of the third fiscal quarter, CEL-SCI reported the results of a bias analysis. The bias analysis, a standard process to ensure a trial's findings are reliable, was conducted in preparation for CEL-SCI's upcoming confirmatory Registration Study. This

    8/15/24 8:00:00 AM ET
    $CVM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    CEL-SCI Appoints Robert Watson as Chairperson of the Board

    CEL-SCI Corporation (NYSE:CVM) today announced that Robert ("Bob") Watson, who has served as a Director of the Company since 2017, has been appointed Chairperson of the Board. Bob is an accomplished business leader who began his career as an investment banker. With over four decades of experience across various healthcare markets, Bob brings extensive expertise in capital formation strategies and partnerships to drive an efficient capital structure. During his career as CEO or President of private and publicly traded companies in the healthcare sector, Bob negotiated over a half dozen exits and more than $750 million in capital transactions including IPOs, secondary offerings, and debt in

    7/8/24 9:15:00 AM ET
    $CVM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    CEL-SCI Appoints Mario Gobbo to Its Board of Directors

    CEL-SCI Corporation (NYSE:CVM) today announced the appointment of Mario Gobbo to its Board of Directors. Mr. Gobbo has nearly 40 years of banking and corporate finance experience in healthcare and energy. His expertise encompasses venture capital and private equity as well as investment banking and strategic advisory services. He has served as an officer or director for a number of companies including several biotech companies: Xcovery, Ocimum/Genelogic and Helix BioPharma. Prior to that, Mr. Gobbo worked in the financial industry for Lazard LLC, Swiss Bank Corporation, the European Bank for Reconstruction and Development, Natixis Bleichroeder, Inc., and International Finance Corporation

    4/23/24 9:00:00 AM ET
    $CVM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care